Drug intelligence / Profile preview

triamcinolone acetonide + sodium hyaluronate + chondroitin sulfate

Development stage: Preclinical
Modality: Small Molecules
Administration: Posterior Juxtascleral Infusion, Intraarticular, Ophthalmic

Overview

A combination drug formulation containing triamcinolone acetonide (a synthetic corticosteroid), sodium hyaluronate (a glycosaminoglycan), and chondroitin sulfate (another glycosaminoglycan). This combination has been studied for its antiangiogenic properties and effectiveness in treating conditions such as diabetic macular edema and potentially joint disorders. The triamcinolone acetonide component provides anti-inflammatory effects, while sodium hyaluronate and chondroitin sulfate contribute viscoelastic and potentially chondroprotective properties.

Targets

PLA2 (Phospholipase A2 group IID)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on triamcinolone acetonide + sodium hyaluronate + chondroitin sulfate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on triamcinolone acetonide + sodium hyaluronate + chondroitin sulfate.

Explore the full profile